Post by
WarrantOfficer on Jan 02, 2024 9:19am
From 21 Dec 2023 PR
"Voyageur is in talks currently with potential drug development research firms to launch the drug development program. However, their clinical adoption is contingent upon continued research, clinical validation to confirm their safety and efficacy and regulatory approvals"
I assume when Voyageur states "their clinical adaptation" they are in fact refering to the drug development research firms.
Comment by
postie1 on Jan 02, 2024 9:47am
That is what I am thinking so IMO it is current products first and money flow to step up research. Plus is it VM or Raincage or both that is doing the testing to date because if they have deep pockets that would be a big help.
Comment by
lscfa on Jan 02, 2024 10:37am
Sounds like VM/RC will do the safety/efficacy tests and then a drug development firm will do the formulation into a contrast product.